VERQUVO (vericiguat)
SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS · HEART FAILURE WITH REDUCED EJECTION FRACTION
Merck Sharp & Dohme
Drug class
Soluble Guanylate Cyclase (sGC) Stimulators
Soluble guanylate cyclase (sGC) stimulators are a distinct class of cardiopulmonary agents that enhance intracellular cyclic guanosine monophosphate (cGMP) production to promote vasodilation and protect vascular and myocardial tissues. Read more about Soluble Guanylate Cyclase (sGC) Stimulators
1 drugs in this class 1 manufacturers
Drugs in Soluble Guanylate Cyclase (sGC) Stimulators
Filter & compare in the drug finder →
Opens the drug finder with Soluble Guanylate Cyclase (sGC) Stimulators preselected. Add indication or manufacturer filters there.
Soluble guanylate cyclase (sGC) stimulators are a distinct class of cardiopulmonary agents that enhance intracellular cyclic guanosine monophosphate (cGMP) production to promote vasodilation and protect vascular and myocardial tissues.
They exert their therapeutic effects through a dual mechanism by directly stimulating sGC via a binding site independent of nitric oxide (NO) while simultaneously sensitizing the enzyme to endogenous NO.
Because they operate effectively even under conditions of endothelial dysfunction and reduced NO bioavailability, these medications are primarily utilized in the management of pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and symptomatic chronic heart failure with reduced ejection fraction.
-
fda.gov
Soluble guanylate cyclase (sGC) stimulators are a distinct class of cardiopulmonary agents that enhance intracellular cyclic guanosine monophosphate (cGMP) production to promote vasodilation and protect vascular and myocardial tissues They exert their therapeutic effects through a dual mechanism by directly stimulating sGC via a binding site independent of nitric oxide (NO) while simultaneously sensitizing the enzyme to endogenous NO
-
fda.gov
Soluble guanylate cyclase (sGC) stimulators are a distinct class of cardiopulmonary agents that enhance intracellular cyclic guanosine monophosphate (cGMP) production to promote vasodilation and protect vascular and myocardial tissues They exert their therapeutic effects through a dual mechanism by directly stimulating sGC via a binding site independent of nitric oxide (NO) while simultaneously sensitizing the enzyme to endogenous NO Because they operate effectively even under conditions of endo...
-
fda.gov
Because they operate effectively even under conditions of endothelial dysfunction and reduced NO bioavailability, these medications are primarily utilized in the management of pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and symptomatic chronic heart failure with reduced ejection fraction
-
fda.gov
Because they operate effectively even under conditions of endothelial dysfunction and reduced NO bioavailability, these medications are primarily utilized in the management of pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and symptomatic chronic heart failure with reduced ejection fraction
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.